Skip to content
Screener

Neuropace, Inc. NPCE Other Income (Expense)

Other Income (Expense) at other companies

Medtronic logo
MedtronicMDT
$137M
LivaNova logo
LivaNovaLIVN
-$23.83M-460%
ClearPoint Neuro logo
ClearPoint NeuroCLPT
-$35K-975%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$4.19M+51.6%
Inspire Medical Systems logo
Inspire Medical SystemsINSP
-$226K-104%
CVRx, Inc. logo
CVRx, Inc.CVRX
$560K-49.5%

Other financials

Income statement

See full
Revenue$22.8M+17.1%
Gross profit$18.9M+16.6%
Operating income-$5.1M+37.2%
Net income-$6.2M+28.3%
EPS (diluted)-$0.18+30.8%

Balance sheet

See full
Cash & equivalents$12.8M-44.4%
Total debt$69.9M-2.2%
Total equity$11.9M-38.9%
Total assets$97.0M-8.6%

Cash flow

See full
Operating cash flow-$3.9M-87.1%
CapEx$125.0K-25.6%
Free cash flow-$4.0M-78.7%

Valuation

See full
Market cap$505.61M+73.4%
Enterprise value$562.76M+65.5%
P/S5.1×+1.7×

Profitability

See full
Gross margin79.6%+2.6pp
Operating margin-15.3%-4.3pp
Net margin-19.3%-5.2pp
FCF margin-12.2%-3.3pp

Returns & leverage

See full
Return on equity-122.1%-28.9pp
Debt / equity5.9×+2.2×
Current ratio4.9×-0.5×

Where this comes from

Reported directly by Neuropace, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The source filing: Neuropace, Inc.’s 10-Q, filed August 11, 2026.

Filed
Aug 11, 2026, 4:33 PM EDT
Fiscal quarter
Q4 FY2030
Calendar quarter
Q4 2030
Accession
0001528287-26-000030
(in thousands, except for share and per share amounts)Three Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Loss from continuing operations(5,143)(8,189)(10,748)(14,949)
Interest income5237181,0881,511
Interest expense(1,539)(2,059)(3,060)(4,212)
Other income (expense), net(41)(486)(206)(568)
Net loss and comprehensive loss from continuing operations(6,200)(10,016)(12,926)(18,218)
Net income from discontinued operations1,365372,978
Net loss and comprehensive loss$(6,200)$(8,651)$(12,889)$(15,240)
Net loss per share from continuing operations attributable to common stockholders, basic and diluted$(0.18)$(0.30)$(0.38)$(0.57)

Item 1. Financial Statements (Unaudited)

FAQ

What is Neuropace, Inc.'s other income (expense)?
Neuropace, Inc. (NPCE) reported other income (expense) of -$41K in Q2 2026.
How has Neuropace, Inc.'s other income (expense) changed year-over-year?
Neuropace, Inc.'s other income (expense) increased by 91.6% year-over-year, from -$486K to -$41K.
What is the long-term trend for Neuropace, Inc.'s other income (expense)?
Over 2 years (2021 to 2025), Neuropace, Inc.'s other income (expense) has grown at a -69.9% compound annual growth rate (CAGR), from -$5.38M to -$486K.
What does other income (expense) mean?
Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.

Ask your AI about Neuropace, Inc.'s other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude